These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6180128)

  • 61. Managing the adverse effects of interferon-beta therapy in multiple sclerosis.
    Bayas A; Rieckmann P
    Drug Saf; 2000 Feb; 22(2):149-59. PubMed ID: 10672896
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Catabolism of interferons.
    Bocci V
    Surv Immunol Res; 1982; 1(2):137-43. PubMed ID: 6195713
    [No Abstract]   [Full Text] [Related]  

  • 63. The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma.
    Bocci V; Muscettola M; Grasso G; Magyar Z; Naldini A; Szabo G
    Experientia; 1986 Apr; 42(4):432-3. PubMed ID: 3956696
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics of recombinant interferon alpha-C.
    Merimsky O; Rubinstein M; Fischer D; Danon A; Chaitchik S
    Cancer Chemother Pharmacol; 1991; 27(5):406-8. PubMed ID: 1999003
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical pharmacokinetics of interferons.
    Wills RJ
    Clin Pharmacokinet; 1990 Nov; 19(5):390-9. PubMed ID: 1702693
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Metabolism of interferon: hepatic clearance of native and desialylated interferon.
    Bocci V; Pacini A; Pessina GP; Bargigli V; Russi M
    J Gen Virol; 1977 Jun; 35(3):525-34. PubMed ID: 881617
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of sialic acid in determining the survival of circulating interferon.
    Bocci V; Pacini A; Pessina GP; Bargigli V; Russi M
    Experientia; 1977 Feb; 33(2):164-6. PubMed ID: 844537
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Renal metabolism of homologous serum interferon.
    Bocci V; Di Francesco P; Pacini A; Pessina GP; Rossi GB; Sorrentino V
    Antiviral Res; 1983 Mar; 3(1):53-8. PubMed ID: 6191655
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differences in sialic acid content of human interferons.
    Morser J; Kabayo JP; Hutchinson DW
    J Gen Virol; 1978 Oct; 41(1):175-8. PubMed ID: 702115
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The role of liver in the catabolism of human alpha- and beta-interferon.
    Bocci V; Pacini A; Bandinelli L; Pessina GP; Muscettola M; Paulesu L
    J Gen Virol; 1982 Jun; 60(Pt 2):397-400. PubMed ID: 6180128
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA).
    Thomas P; Zamcheck N
    Dig Dis Sci; 1983 Mar; 28(3):216-24. PubMed ID: 6337795
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Distribution of interferon in body fluids and tissues.
    Bocci V
    Tex Rep Biol Med; 1977; 35():436-42. PubMed ID: 358467
    [No Abstract]   [Full Text] [Related]  

  • 73. Binding of drugs to alpha 1-acid glycoprotein and its desialylated form. Influence on hepatic disposition and implications for drug targeting to the liver.
    Meijer DK; van der Sluijs P
    Prog Clin Biol Res; 1989; 300():143-67. PubMed ID: 2674961
    [No Abstract]   [Full Text] [Related]  

  • 74. Recombinant human interferons.
    Otto B
    Arzneimittelforschung; 1985; 35(11):1750-2. PubMed ID: 2418848
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.